Value Sense
DXCM
DexCom, Inc. (DXCM)
Last Price$86.0(2.7%)
Market Cap$34.9B
Intrinsic value score
7/10
Great
Intrinsic value
$43.1
DCF value - $38.9 Relative value - $47.4
Overvalued
49.8%
LTM P/E
60.6x
Peer set median 32.4x
Discount rate
8.9%
DXCM
is 49.8% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

DXCM Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 03, 2025 DXCM Relative Value is $48.2, which is overvalued by 43.9%, compared to current share price of $86.0.
DCF Value vs Current Share Price
As of Mar 03, 2025 DXCM DCF Value is $39.0, which is overvalued by 54.7%, compared to current share price of $86.0.
Methodology
Price per share, $
DXCM
Intrinsic value$43.1
Overvalued by49.8%
Current share price
86.0
Relative value
48.2
DCF value
39.0

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

DXCM Historical Intrinsic Value

Crunching data... Almost there!

DXCM vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

DexCom, Inc. logo
DexCom, Inc.DXCM
(49.8%)
11.3%
(1.4%)
14.3%
Median Peer Set
4.1%
126.3%
11.8%
Boston Scientific Corporation logo
Boston Scientific CorporationBSX
(67.4%)
17.6%
16.7%
11.1%
Insulet Corporation logo
Insulet CorporationPODD
(50.7%)
30.0%
4,364.6%
12.2%
Edwards Lifesciences Corporation logo
Edwards Lifesciences CorporationEW
(24.2%)
(9.4%)
202.2%
76.7%
Stryker Corporation logo
Stryker CorporationSYK
(22.7%)
10.2%
(5.8%)
13.2%
STERIS plc logo
STERIS plcSTE
(10.4%)
3.6%
257.9%
7.4%
Align Technology, Inc. logo
Align Technology, Inc.ALGN
8.5%
3.4%
26.0%
11.5%
Medtronic plc logo
Medtronic plcMDT
21.5%
3.6%
(2.1%)
11.4%
Abbott Laboratories logo
Abbott LaboratoriesABT
24.5%
4.6%
134.5%
31.9%
Zimmer Biomet Holdings, Inc. logo
Zimmer Biomet Holdings, Inc.ZBH
72.0%
6.5%
253.2%
13.8%
Koninklijke Philips N.V. logo
Koninklijke Philips N.V.PHG
146.8%
(0.8%)
118.1%
(3.9%)

Explore more intrinsic value tools hub for DXCM

Peter Lynch Fair Value
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
Earnings growth model
DCF value calculator
Discount rate
Peter Lynch charts
Reverse DCF
Relative Value

FAQ

What is DexCom, Inc. intrinsic value?

As of Mar 03, 2025, DexCom, Inc. Intrinsic Value is $43.1. This suggests it may be overvalued by 49.8% compared to its current price of around $86.0.

What is DexCom, Inc. DCF (discounted cash flow) valuation?

As of Mar 03, 2025, DexCom, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $39.0. This suggests it may be overvalued by 54.7% to its current price of around $86.0, using a discount rate of 8.9% and terminal growth rate of 3.0%.

Is DexCom, Inc. overvalued or undervalued?

DexCom, Inc. is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $43.1, compared to a market price of around $86.0. This suggests a potential overvaluation of 49.8%.